Oscotec Inc.

Translating science into medicine
Sign Up
 회사연혁

Oscotec Inc. History


2020

  1. Mar. Dr. Yoon Taeyoung inaugurated as Separate CEO

2019

  1. Oct. Initiation of SYK inhibitor's Phase 2 clinical trial for ITP drug candidate

2018

  1. Nov. L/O of EGFR-Targeted Anti-Cancer Drug (Yuhan yo Janssen Biotech.)
  2. Oct. Drug candidate for Reumotoid Arthritis selected as KDDF sponsored Project (Phase 2 clinical trial)

2017

  1. Dec. Commencement of Phase 1 clinical trial of FLT3-Targeted drug candidate for AML
  2. Jul. Completion of SYK inhibitor's FDA Phase 1 clinical trial for Reumotoid Arthritis in US

2016

  1. Oct. Approval for Phase 1 clinical trial of FLT3-Targeted drug candidate fot AML
  2. Oct. IND and CTA of FLT3, AML drug
  3. Apr. GENOSCO separated into R&D company (Moved to Head quarter in Boston)
  4. Jan. Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for Rheumatoid Arthritis

2015

  1. Dec. Complete in Pre-clinical study for AML drug
  2. Sep. IND and CTA of SYK, inhibitor Rheumatoid Arthritis
  3. Jul. Licensing Out EGFR, non-small-cell-lung-cancer drug candidate
  4. Apr. Porcine pericardium membrane LysoGide approved and production begins

2014

  1. Jun. Selected for Ministry of Health & Welfare’s R&D project Development of FLT3 inhibitor for the treatment of acute myeloid leukemia
  2. May Selected for Korea Drug Development Fund (KDDF) project Development of SYK inhibitor for rheumatoid Arthritis
  3. Apr. Bone graft BioCera-F approved by KFDA and production begins

2013

  1. Oct. Ministry of Science, ICT and future planning-Development of Novel Drug for Parkinson’s disease

2012

  1. May AML drug pre-clinical test

2011

  1. Aug. R&D Center moved into Korea Bio Park and expanded to become Oscotec Central R&D Center
  2. Jun. Commercial production and sales of InduCera
More View
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.